Global Orally Disintegrating Tablets 麻豆原创 Growth 2024-2030

Publication ID:

LPI12247266

Publication Date:

December 24, 2024

Pages:

107

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Orally Disintegrating Tablets market size was valued at US$ 13590 million in 2023. With growing demand in downstream market, the Orally Disintegrating Tablets is forecast to a readjusted size of US$ 30300 million by 2030 with a CAGR of 12.1% during review period.
The research report highlights the growth potential of the global Orally Disintegrating Tablets market. Orally Disintegrating Tablets are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Orally Disintegrating Tablets. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Orally Disintegrating Tablets market.
An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
Global Orally Disintegrating Tablet main manufactuers include Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb and Conquer, totally accounting for about 17% of the market. North America is the largest market of glass packaging, holding a share more than 40%. As for the types of products, it can be divided into anti-psychotics drug, anti-epileptics drug and others. As for the applications of products, it is widely used in CNS diseases, gastrointestinal diseases, CVS diseases and others. The most common application is in CNS diseases packaging, with a share about 55%.
Key Features:
The report on Orally Disintegrating Tablets market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Orally Disintegrating Tablets market. It may include historical data, market segmentation by Type (e.g., Anti-Psychotics Drug, Anti-Epileptics Drug), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Orally Disintegrating Tablets market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Orally Disintegrating Tablets market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Orally Disintegrating Tablets industry. This include advancements in Orally Disintegrating Tablets technology, Orally Disintegrating Tablets new entrants, Orally Disintegrating Tablets new investment, and other innovations that are shaping the future of Orally Disintegrating Tablets.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Orally Disintegrating Tablets market. It includes factors influencing customer ' purchasing decisions, preferences for Orally Disintegrating Tablets product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Orally Disintegrating Tablets market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Orally Disintegrating Tablets market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Orally Disintegrating Tablets market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Orally Disintegrating Tablets industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Orally Disintegrating Tablets market.
麻豆原创 Segmentation:
Orally Disintegrating Tablets market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segmentation by application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer
Key Questions Addressed in this Report
What is the 10-year outlook for the global Orally Disintegrating Tablets market?
What factors are driving Orally Disintegrating Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Orally Disintegrating Tablets market opportunities vary by end market size?
How does Orally Disintegrating Tablets break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Orally Disintegrating Tablets Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Orally Disintegrating Tablets by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Orally Disintegrating Tablets by Country/Region, 2019, 2023 & 2030
2.2 Orally Disintegrating Tablets Segment by Type
2.2.1 Anti-Psychotics Drug
2.2.2 Anti-Epileptics Drug
2.2.3 Other
2.3 Orally Disintegrating Tablets Sales by Type
2.3.1 Global Orally Disintegrating Tablets Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Orally Disintegrating Tablets Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Orally Disintegrating Tablets Sale Price by Type (2019-2024)
2.4 Orally Disintegrating Tablets Segment by Application
2.4.1 CNS Diseases
2.4.2 Gastrointestinal Diseases
2.4.3 CVS Diseases
2.4.4 Other
2.5 Orally Disintegrating Tablets Sales by Application
2.5.1 Global Orally Disintegrating Tablets Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Orally Disintegrating Tablets Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Orally Disintegrating Tablets Sale Price by Application (2019-2024)
3 Global Orally Disintegrating Tablets by Company
3.1 Global Orally Disintegrating Tablets Breakdown Data by Company
3.1.1 Global Orally Disintegrating Tablets Annual Sales by Company (2019-2024)
3.1.2 Global Orally Disintegrating Tablets Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Orally Disintegrating Tablets Annual Revenue by Company (2019-2024)
3.2.1 Global Orally Disintegrating Tablets Revenue by Company (2019-2024)
3.2.2 Global Orally Disintegrating Tablets Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Orally Disintegrating Tablets Sale Price by Company
3.4 Key Manufacturers Orally Disintegrating Tablets Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Orally Disintegrating Tablets Product Location Distribution
3.4.2 Players Orally Disintegrating Tablets Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Orally Disintegrating Tablets by Geographic Region
4.1 World Historic Orally Disintegrating Tablets 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Orally Disintegrating Tablets Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Orally Disintegrating Tablets Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Orally Disintegrating Tablets 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Orally Disintegrating Tablets Annual Sales by Country/Region (2019-2024)
4.2.2 Global Orally Disintegrating Tablets Annual Revenue by Country/Region (2019-2024)
4.3 Americas Orally Disintegrating Tablets Sales Growth
4.4 APAC Orally Disintegrating Tablets Sales Growth
4.5 Europe Orally Disintegrating Tablets Sales Growth
4.6 Middle East & Africa Orally Disintegrating Tablets Sales Growth
5 Americas
5.1 Americas Orally Disintegrating Tablets Sales by Country
5.1.1 Americas Orally Disintegrating Tablets Sales by Country (2019-2024)
5.1.2 Americas Orally Disintegrating Tablets Revenue by Country (2019-2024)
5.2 Americas Orally Disintegrating Tablets Sales by Type
5.3 Americas Orally Disintegrating Tablets Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Orally Disintegrating Tablets Sales by Region
6.1.1 APAC Orally Disintegrating Tablets Sales by Region (2019-2024)
6.1.2 APAC Orally Disintegrating Tablets Revenue by Region (2019-2024)
6.2 APAC Orally Disintegrating Tablets Sales by Type
6.3 APAC Orally Disintegrating Tablets Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Orally Disintegrating Tablets by Country
7.1.1 Europe Orally Disintegrating Tablets Sales by Country (2019-2024)
7.1.2 Europe Orally Disintegrating Tablets Revenue by Country (2019-2024)
7.2 Europe Orally Disintegrating Tablets Sales by Type
7.3 Europe Orally Disintegrating Tablets Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Orally Disintegrating Tablets by Country
8.1.1 Middle East & Africa Orally Disintegrating Tablets Sales by Country (2019-2024)
8.1.2 Middle East & Africa Orally Disintegrating Tablets Revenue by Country (2019-2024)
8.2 Middle East & Africa Orally Disintegrating Tablets Sales by Type
8.3 Middle East & Africa Orally Disintegrating Tablets Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Orally Disintegrating Tablets
10.3 Manufacturing Process Analysis of Orally Disintegrating Tablets
10.4 Industry Chain Structure of Orally Disintegrating Tablets
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Orally Disintegrating Tablets Distributors
11.3 Orally Disintegrating Tablets Customer
12 World Forecast Review for Orally Disintegrating Tablets by Geographic Region
12.1 Global Orally Disintegrating Tablets 麻豆原创 Size Forecast by Region
12.1.1 Global Orally Disintegrating Tablets Forecast by Region (2025-2030)
12.1.2 Global Orally Disintegrating Tablets Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Orally Disintegrating Tablets Forecast by Type
12.7 Global Orally Disintegrating Tablets Forecast by Application
13 Key Players Analysis
13.1 Teva
13.1.1 Teva Company Information
13.1.2 Teva Orally Disintegrating Tablets Product Portfolios and Specifications
13.1.3 Teva Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Teva Main Business Overview
13.1.5 Teva Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Orally Disintegrating Tablets Product Portfolios and Specifications
13.2.3 Merck Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Mylan
13.3.1 Mylan Company Information
13.3.2 Mylan Orally Disintegrating Tablets Product Portfolios and Specifications
13.3.3 Mylan Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Mylan Main Business Overview
13.3.5 Mylan Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Orally Disintegrating Tablets Product Portfolios and Specifications
13.4.3 Pfizer Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Johnson and Johnson
13.5.1 Johnson and Johnson Company Information
13.5.2 Johnson and Johnson Orally Disintegrating Tablets Product Portfolios and Specifications
13.5.3 Johnson and Johnson Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Johnson and Johnson Main Business Overview
13.5.5 Johnson and Johnson Latest Developments
13.6 GSK
13.6.1 GSK Company Information
13.6.2 GSK Orally Disintegrating Tablets Product Portfolios and Specifications
13.6.3 GSK Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 GSK Main Business Overview
13.6.5 GSK Latest Developments
13.7 Otsuka
13.7.1 Otsuka Company Information
13.7.2 Otsuka Orally Disintegrating Tablets Product Portfolios and Specifications
13.7.3 Otsuka Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Otsuka Main Business Overview
13.7.5 Otsuka Latest Developments
13.8 Eli Lilly and Company
13.8.1 Eli Lilly and Company Company Information
13.8.2 Eli Lilly and Company Orally Disintegrating Tablets Product Portfolios and Specifications
13.8.3 Eli Lilly and Company Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Eli Lilly and Company Main Business Overview
13.8.5 Eli Lilly and Company Latest Developments
13.9 AstraZeneca
13.9.1 AstraZeneca Company Information
13.9.2 AstraZeneca Orally Disintegrating Tablets Product Portfolios and Specifications
13.9.3 AstraZeneca Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 AstraZeneca Main Business Overview
13.9.5 AstraZeneca Latest Developments
13.10 Bristol-Myers Squibb
13.10.1 Bristol-Myers Squibb Company Information
13.10.2 Bristol-Myers Squibb Orally Disintegrating Tablets Product Portfolios and Specifications
13.10.3 Bristol-Myers Squibb Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Bristol-Myers Squibb Main Business Overview
13.10.5 Bristol-Myers Squibb Latest Developments
13.11 Conquer
13.11.1 Conquer Company Information
13.11.2 Conquer Orally Disintegrating Tablets Product Portfolios and Specifications
13.11.3 Conquer Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Conquer Main Business Overview
13.11.5 Conquer Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.